News | December 03, 2010

Cardiac Resynchronization Therapy Shown to be Cost-Effective

December 3, 2010 – For the first time, data has shown that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients. Data from an economic sub-study of the REVERSE trial was published in the European Heart Journal.

The results showed a €14,278 per quality adjusted life years (QALY) gained for CRT, compared to the commonly used European willingness to pay (WTP) threshold of €33,000 per QALY gained. Additionally, patients receiving CRT are estimated to gain almost one full year (0.94) or 0.80 QALYs compared to the group not receiving CRT, at an additional cost of €11,455, over ten years.

"While prior studies have proven the numerous benefits and cost-effectiveness of CRT in treating symptomatic heart failure patients, now for the first time, these data show that CRT not only helps keep less sick heart failure patients out of the hospital more, but it is also a more cost-effective treatment approach than many other therapeutic options currently available,” said Cecilia Linde, M.D., Ph.D., Karolinska University, Stockholm, Sweden. “We look forward to conducting additional analyses demonstrating the economic value of this treatment approach in a mildly symptomatic patient population.”

An economic model was developed to predict the effect of CRT on life years, QALYs and costs over time periods up to 10 years. The economic analysis was based on clinical data that showed at 24 months a worsening of heart failure in 34 percent of patients who did not have CRT therapy, compared with 19 percent of patients who did. Additionally, the time to first heart failure hospitalization was significantly longer in the CRT-on than the CRT-off group (hazard ratio = 0.39, p

CRT uses a stopwatch-sized implantable device to resynchronize the contractions of the ventricles by sending tiny electrical impulses to the heart muscle. Resynchronizing the contractions of the ventricles may help the heart pump blood throughout the body more efficiently and reduce symptoms.

The trial did not meet statistical significance for its primary endpoint (percent of patients worsened at 12 months). However, patients experienced a significant improvement in cardiac function and reduction in HF hospitalizations. Furthermore, the European sub-group, which was followed through 24 months, demonstrated statistical significance for the same endpoint (19 percent versus 34 percent worsened in the CRT-on and -off groups, p = 0.01).

For more information: www.medtronic.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init